Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Mahner, Sven, Woelber, Linn, Mueller, Volkmar, Witzel, Isabell, Prieske, Katharina, Grimm, Donata, Keller-v Amsberg, Gunhild, Trillsch, Fabian
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2015
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4593253/
https://ncbi.nlm.nih.gov/pubmed/26500886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2015.00211
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares